Adenosine: nootropics and compounds | sci-wiki

Sipagladenant

Sipagladenant (development code KW-6356; CAS 858979-50-7) is an investigational, orally active, highly selective antagonist and inverse agonist of the adenosine A2A receptor developed by Kyowa Kirin for Parkinson's disease. It belongs to the non-dopaminergic class of antiparkinsonian agents typified by istradefylline, but in vitro studies distinguish it by insurmountable antagonism, very slow receptor dissociation, and inverse-agonist activity that suppresses the constitutive signaling of the A2A receptor. Because A2A receptors are densely co-expressed with dopamine D2 receptors as A2A-D2 heteromers on striatopallidal neurons of the indirect motor pathway, blockade of A2A relieves the adenosine-mediated brake on D2 signaling and improves motor output without directly stimulating dopamine receptors. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated marmosets it reversed motor disability as monotherapy, produced greater anti-parkinsonian activity than istradefylline, and potentiated levodopa with a low propensity to induce dyskinesia; a placebo-controlled trial in early, untreated Parkinson's disease reported improvement in MDS-UPDRS Part III scores. Sipagladenant remains a clinical-stage compound; it is not approved for any indication, and much of its long-term efficacy and safety profile is still being characterized.

1 outlet

Stimulant

8-Chlorotheophylline

8-Chlorotheophylline is a xanthine stimulant closely related to caffeine and theophylline. Its best-known role is as the mild stimulant half of Dramamine (dimenhydrinate), where it is paired with the sedating antihistamine diphenhydramine to offset its drowsiness. On its own it is a modest caffeine-like stimulant rather than a strong recreational drug.

reference

Cannabinoid

Cannabichromene

Cannabichromene (CBC) is a non-psychotropic phytocannabinoid and one of the six most abundant cannabinoids in Cannabis sativa, biosynthesized from cannabigerolic acid (CBGA) via the enzyme CBCA synthase and decarboxylated from its acidic precursor cannabichromenic acid. Structurally a resorcinol-derived chromene rather than the classic dibenzopyran of THC, it binds the classical cannabinoid receptors only weakly and instead acts primarily as a potent agonist of the TRPA1 ion channel while inhibiting the cellular reuptake and degradation of the endocannabinoid anandamide. Preclinical studies describe anti-inflammatory, gastrointestinal-normalizing, antidepressant-like, analgesic, antimicrobial and neural stem-cell-supporting activity, and CBC is frequently cited as a contributor to the "entourage effect" of whole-plant cannabis. It is not scheduled as a distinct controlled substance in most jurisdictions but is regulated as a cannabis constituent, and its clinical evidence base in humans remains early-stage.

reference

Respiratory

Dyphylline

Dyphylline is a xanthine-derivative bronchodilator that relaxes airway smooth muscle through nonselective phosphodiesterase inhibition and weak adenosine-receptor antagonism. Chemically 7-(2,3-dihydroxypropyl)-1,3-dimethylxanthine, it is a distinct synthetic methylxanthine rather than a theophylline salt, and unlike theophylline it is not metabolized to theophylline in the body but is instead cleared largely unchanged by the kidneys. Marketed for decades under names such as Dilor and Lufyllin (often combined with the expectorant guaifenesin), it is an FDA-approved agent used for the symptomatic relief of bronchospasm in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. Compared with theophylline it is a somewhat weaker bronchodilator on a milligram basis but carries a wider tolerability margin, a shorter half-life, and far fewer drug and smoking interactions because it bypasses hepatic CYP1A2 metabolism. More recent laboratory work has explored repurposing dyphylline as a coronavirus main-protease inhibitor and as a cAMP-raising activator of dormant ovarian follicles.

reference

Stimulant

IBMX

IBMX (3-isobutyl-1-methylxanthine) is a synthetic methylxanthine and nonselective phosphodiesterase inhibitor that also antagonizes adenosine receptors, widely used as a research reagent to raise intracellular cAMP and cGMP. It inhibits most cyclic-nucleotide phosphodiesterase families in the low-micromolar range while comparatively sparing PDE8 and PDE9, and it is a standard component of cell-differentiation cocktails for adipocytes and melanocytes as well as a common positive control in phosphodiesterase and adenosine-receptor pharmacology assays.

reference

Nootropic

Istradefylline

Istradefylline is a selective adenosine A2A receptor antagonist used as an add-on to levodopa-based therapy in adults with Parkinson's disease. It is taken to reduce daily off episodes, the stretches of the day when dopaminergic medication wears off and motor symptoms return [1][2]. Structurally a xanthine derivative, it was the first drug of its class to reach the market and acts through a non-dopaminergic pathway distinct from conventional Parkinson's treatments [1].

reference

Nootropic

Theophylline

Theophylline is a naturally occurring methylxanthine (1,3-dimethylxanthine) that has been used as a bronchodilator and respiratory stimulant for more than 80 years. Structurally related to caffeine and theobromine and found in trace amounts in tea and cocoa, it relaxes airway smooth muscle and stimulates respiration through a combination of non-selective phosphodiesterase inhibition and adenosine receptor antagonism. At the low plasma concentrations achieved with modern sustained-release dosing, it also exerts anti-inflammatory effects by restoring histone deacetylase-2 (HDAC2) activity, a mechanism that can reverse corticosteroid resistance in severe asthma and chronic obstructive pulmonary disease (COPD). Because it has a narrow therapeutic window and numerous drug interactions, it is now generally reserved as an add-on therapy after inhaled agents.

reference